Standard Biotools (LAB) Cash from Investing Activities Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn | -208.79% |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn | -397.90% |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn | -514.25% |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | -158.60% |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn | 1,206.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,206.60% |
| Dec 31, 2025 | -131.25% |
| Sep 30, 2025 | 78.37% |
| Jun 30, 2025 | -45.27% |
| Mar 31, 2025 | -95.40% |
| Dec 31, 2024 | 296.13% |
| Sep 30, 2024 | 38.14% |
| Jun 30, 2024 | 25.25% |
| Mar 31, 2024 | 637.07% |
| Dec 31, 2023 | -132.59% |
| Sep 30, 2023 | -565.03% |
| Jun 30, 2023 | 129.03% |
| Mar 31, 2023 | 5,071.66% |
| Sep 30, 2022 | 199.40% |
| Jun 30, 2022 | -1,419.96% |
| Mar 31, 2022 | 82.37% |
| Sep 30, 2021 | -181.76% |
| Jun 30, 2021 | -189.82% |
| Mar 31, 2021 | -128.20% |
| Dec 31, 2020 | -49.18% |